Table 1.
Completed clinical studies of MSCs in the treatment of patients with ARDS.
| Numbers | Trial ID | Sources of MSCs | Phase | Numbers of patients | Doses and administration routes | Primary outcomes | Refs. |
|---|---|---|---|---|---|---|---|
| 1 | NCT01902082 | AD-MSCs | 1 | 12 | A single dose of 1 × 106 cells/ kg; IV | No adverse events or serious adverse events. The clinical effect at this dose is weak. | 71 |
| 2 | Not reported | BM-MSCs | Case report | 2 | A single dose of 2 × 106 cells/ kg; IV | Oxygenation and pulmonary compliance were improved. Levels of inflammation markers were reduced. | 72 |
| 3 | Not reported | UC-MSCs | 1 | 9 | A single dose of 1.0 × 106 cells/kg or 5.0 × 106 cells/kg or 1.0 × 107 cells/kg;IV | Tolerated without serious adverse events. | 73 |
| 4 | NCT01775774 | BM-MSCs | 1 | 9 | A single dose of 1 × 106 cells/kg or 5 × 106 cells/kg or 10 × 106 cells/kg;IV | Well tolerated and safe. | 74 |
| 5 | NCT02097641 | BM-MSCs | 2a | 60 | A single dose of 10 × 106 cells/kg; IV | No MSC-related predefined hemodynamic or respiratory adverse events. | 75 |
| 6 | NCT03042143. | UC-MSCs | 1 | 9 | A single dose of 1 or 2 or 4 × 108; IV | Well tolerated. Adverse events included apyrexia, non-sustained ventricular tachycardia, and deranged liver function. | 76 |
MSCs, mesenchymal stem cells; AD-MSCs, adipose-derived MSCs; BM-MSCs, bone marrow autologous MSCs; UC-MSCs, umbilical cord-derived MSCs; IV, intravenous injection.